Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Transparent practices: Suppliers who clearly communicate their sourcing, testing, and handling practices demonstrate commitment to quality
Directed human clinical trials are necessary to validate BPC-157's efficacy in musculoskeletal injury, gastrointestinal, and vascular disorders that show promise in preclinical models
Industry testing has shown that peptide purity across unregulated or unverified suppliers can vary dramatically with some analyses finding purity levels far below the 98%+ threshold considered standard for reliable research use
animal studies suggest it may support healing of gastric ulcers and damaged intestinal lining Preclinical models suggest it may help modulate inflammation, though this has not been established in controlled human trials Known risks and side effects: Because it is sold as an unregulated research chemical rather than a manufactured pharmaceutical, product purity and dosing accuracy cannot be verified, and the FDA has flagged potential impurities and manufacturing-quality concerns FDA's Category 2 determination specifically cited potential immune reactions and hypersensitivity as a safety concern User-reported (non-clinical-trial) effects include injection-site irritation, redness, or swelling, along with occasional headache, nausea, or lightheadedness, based on anecdotal reporting rather than controlled studies No long-term human safety data exists
GH secretagogues work best on an empty stomach, typically before bed or upon waking
Data are limited, the risk is theoretical and requires thorough investigation prior to administration in individuals attempting conception
